Literature DB >> 23603341

Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer.

Sandra F Martins1, Eduardo A Garcia, Marcus Alexandre Mendes Luz, Fernando Pardal, Mesquita Rodrigues, Adhemar Longatto Filho.   

Abstract

BACKGROUND: Colorectal cancer (CRC) is the third most common type of cancer and the fourth most frequent cause of cancer death. Literature indicates that vascular endothelial growth factor is a predominant angiogenic factor and that angiogenesis plays an important role in the progression of CRC. PATIENTS AND METHODS: The present series consisted of tissue samples obtained from 672 patients who had undergone large bowel resection between 2005 and 2010 at the Braga Hospital, Portugal. Archival paraffin-embedded CRC tissue and normal adjacent samples were used to build up tissue microarray blocks and VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression was immunohistochemically assessed.
RESULTS: We observed an overexpression of VEGF-C in CRC when tumour cells and normal-adjacent tissue were compared (p=0.004). In tumour samples, VEGF-C-positive cases were associated with VEGFR-3 expression (p=0.047). When assessing the correlation between VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expressions and the clinicopathological data, it was revealed that VEGF-A positive cases were associated with male gender (p=0.016) and well-differentiated tumours (p=0.001); VEGF-C with colon cancers (p=0.037), exophytic (p=0.048), moderately-differentiated (p=0.007) and T3/T4 (p=0.010) tumours; VEGFR-2 with invasive adenocarcinoma (p=0.007) and VEGFR-3 with the presence of hepatic metastasis (p=0.032). Overall survival curves for CRC were statistically significant for rectal cancer, VEGF-C expression and stage III (p=0.019) and VEGFR-3 expression and stage IV (p=0.047).
CONCLUSION: Quantification of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression seems to provide valuable prognostic information in CRC and the correlation with clinicopathological data revealed an association with characteristics that contribute to progression, invasion and metastasis leading to poorer survival rates and prognosis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23603341

Source DB:  PubMed          Journal:  Cancer Genomics Proteomics        ISSN: 1109-6535            Impact factor:   4.069


  47 in total

1.  Overexpression of HOXB9 promotes metastasis and indicates poor prognosis in colon cancer.

Authors:  Kai Huang; Rongfa Yuan; Kai Wang; Junwen Hu; Zixi Huang; Chen Yan; Wei Shen; Jianghua Shao
Journal:  Chin J Cancer Res       Date:  2014-02       Impact factor: 5.087

2.  Comparison of (18)F-fluorodeoxyglucose PET/CT findings with vascular endothelial growth factors and receptors in colorectal cancer.

Authors:  Ahmet Kocael; Betül Vatankulu; Osman Şimşek; Mahir Cengiz; Ahu Kemik; Pınar Kocael; Metin Halaç; Kerim Sönmezoğlu; Kenan Ulualp
Journal:  Tumour Biol       Date:  2015-10-17

3.  MMP-11 and VEGF-C expression correlate with clinical features of colorectal adenocarcinoma.

Authors:  Chun-Jin Xu; Feng Xu
Journal:  Int J Clin Exp Med       Date:  2014-09-15

Review 4.  OX40 as a novel target for the reversal of immune escape in colorectal cancer.

Authors:  Lin-Hai Yan; Xiao-Liang Liu; Si-Si Mo; Di Zhang; Xian-Wei Mo; Wei-Zhong Tang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

5.  Influence of VEGFR and LHCGR on endometrial adenocarcinoma.

Authors:  Alexandra C Kölbl; Amelie E Birk; Christina Kuhn; Udo Jeschke; Ulrich Andergassen
Journal:  Oncol Lett       Date:  2016-07-22       Impact factor: 2.967

6.  Association of insulin-related serum factors with colorectal polyp number and type in adult males.

Authors:  Sarah S Comstock; Diana Xu; Kari Hortos; Bruce Kovan; Sarah McCaskey; Dorothy R Pathak; Jenifer I Fenton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2014-06-24       Impact factor: 4.254

7.  Low thrombospondin 2 expression is predictive of low tumor regression after neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Cheng-Yi Lin; Ching-Yih Lin; I-Wei Chang; Ming-Jen Sheu; Chien-Feng Li; Sung-Wei Lee; Li-Ching Lin; Ying-En Lee; Hong-Lin He
Journal:  Am J Transl Res       Date:  2015-11-15       Impact factor: 4.060

8.  Expression of CD34, VEGFR3 and eosinophil density in selected odontogenic tumors- a pilot study.

Authors:  MohammadSina ArabSheibani; Safoura Seifi; Jahanshah Salehinejad; Ali Bijani
Journal:  J Oral Biol Craniofac Res       Date:  2019-10-03

9.  Correlation between vascular endothelial growth factor-A expression and tumor location and invasion in patients with colorectal cancer.

Authors:  Susanna Hilda Hutajulu; Dewi Kartikawati Paramita; Joyo Santoso; Muhammad Ivan Aulia Sani; Aghnia Amalia; Gatri Wulandari; Ahmad Ghozali; Johan Kurnianda
Journal:  J Gastrointest Oncol       Date:  2018-12

10.  Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy.

Authors:  Qiaoling Sun; Jinghong Zhou; Zheng Zhang; Mingchuan Guo; Junqing Liang; Feng Zhou; Jingwen Long; Wei Zhang; Fang Yin; Huaqing Cai; Haibin Yang; Weihan Zhang; Yi Gu; Liang Ni; Yang Sai; Yumin Cui; Meifang Zhang; Minhua Hong; Junen Sun; Zheng Yang; Weiguo Qing; Weiguo Su; Yongxin Ren
Journal:  Cancer Biol Ther       Date:  2014       Impact factor: 4.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.